Datasets:
Tasks:
Text Classification
Formats:
parquet
Sub-tasks:
multi-label-classification
Languages:
English
Size:
100K - 1M
License:
seq_id
int64 1
1
| medline_ui
int64 87M
87.3M
| mesh_terms
stringlengths 9
510
| title
stringlengths 5
318
| publication_type
stringclasses 43
values | abstract
stringlengths 77
2.73k
| author
stringlengths 5
150
| source
stringlengths 18
57
|
|---|---|---|---|---|---|---|---|
1 | 87,049,087 | Allied Health Personnel/*; Electric Countershock/*; Emergencies; Emergency Medical Technicians/*; Human; Prognosis; Recurrence; Support, U.S. Gov't, P.H.S.; Time Factors; Transportation of Patients; Ventricular Fibrillation/*TH. | Refibrillation managed by EMT-Ds: incidence and outcome without paramedic back-up. | JOURNAL ARTICLE. | Some patients converted from ventricular fibrillation to organized rhythms by defibrillation-trained ambulance technicians (EMT-Ds) will refibrillate before hospital arrival. The authors analyzed 271 cases of ventricular fibrillation managed by EMT-Ds working without paramedic back-up. Of 111 patients initially converted to organized rhythms, 19 (17%) refibrillated, 11 (58%) of whom were reconverted to perfusing rhythms, including nine of 11 (82%) who had spontaneous pulses prior to refibrillation. Among patients initially converted to organized rhythms, hospital admission rates were lower for patients who refibrillated than for patients who did not (53% versus 76%, P = NS), although discharge rates were virtually identical (37% and 35%, respectively). Scene-to-hospital transport times were not predictively associated with either the frequency of refibrillation or patient outcome. Defibrillation-trained EMTs can effectively manage refibrillation with additional shocks and are not at a significant disadvantage when paramedic back-up is not available. | Stults KR; Brown DD. | Am J Emerg Med 8703; 4(6):491-5 |
1 | 87,049,088 | Antidepressive Agents, Tricyclic/*PO; Arrhythmia/PP; California; Electrocardiography; Emergencies; Emergency Service, Hospital/*; Female; Human; Length of Stay; Male; Prognosis; Retrospective Studies; Tachycardia, Sinus/DI/TH. | Tricyclic antidepressant overdose: emergency department findings as predictors of clinical course. | JOURNAL ARTICLE. | There is controversy regarding the appropriate utilization of health care resources in the management of tricyclic antidepressant overdosage. Antidepressant overdose patients presenting to the emergency department (ED) are routinely admitted to intensive care units, but only a small proportion develop cardiac arrhythmias or other complications requiring such an environment. The authors reviewed the findings in 165 patients presenting to an ED with antidepressant overdose. They found that major manifestations of toxicity on ED evaluation (altered mental status, seizures, arrhythmias, and conduction defects) were commonly associated with a complicated hospital course. Patients with the isolated findings of sinus tachycardia or QTc prolongation had no complications. No patient experienced a serious toxic event without major evidence of toxicity on ED evaluation and continued evidence of toxicity during the hospital course. These data support the concept that proper ED evaluation can identify a large body of patients with trivial ingestions who may not require hospital observation. | Foulke GE; Albertson TE; Walby WF. | Am J Emerg Med 8703; 4(6):496-500 |
1 | 87,049,089 | Adult; Aircraft/*; Altitude/*; Blood Gas Monitoring, Transcutaneous/*MT; Conjunctiva/*ME; Female; Human; Male; Monitoring, Physiologic/*MT; Regression Analysis; Transportation of Patients/*MT. | Transconjunctival oxygen monitoring as a predictor of hypoxemia during helicopter transport. | JOURNAL ARTICLE. | As the use of helicopters for air transport of critically ill patients increases, the availability of monitoring devices for physiological parameters during flight becomes important. It has long been known that arterial PO2 (PaO2) decreases during unsupplemented, non-pressurized flight. In this study, the authors examined the use of the transconjunctival oxygen (cjO2) monitor for assessing the adequacy of arterial oxygenation during helicopter flight in four healthy volunteers. Arterial PaO2 as measured by conventional blood gas analysis was compared with cjO2 at ground level, 5,000 feet, and 10,000 feet altitude. Mean PaO2 dropped significantly from 93.5 to 81.5 to 58.5 mm Hg, respectively (P less than 0.001, analysis of variance with repeated measures). Mean cjO2 also decreased significantly from 63.8 to 52.0 to 34.8 mm Hg, respectively (P less than 0.001, analysis of variance with repeated measures). Within individual subjects, cjO2 was an accurate predictor of PaO2 (P less than 0.001, multiple regression analysis). The relationship between cjO2 and PaO2 was linear with a regression coefficient of 1.147. The authors conclude that the transconjunctival O2 monitor may be useful for monitoring the adequacy of arterial oxygenation during helicopter flight in hemodynamically stable patients. The results of study also support the use of supplemental oxygen in all patients subjected to helicopter transport. | Shufflebarger C; Jehle D; Cottington E; Martin M. | Am J Emerg Med 8703; 4(6):501-3 |
1 | 87,049,090 | Adolescence; Adult; Aged; Blood Glucose/*ME; Diabetes Mellitus/BL; Emergencies; Female; Glucose/*AD; Human; Hypoglycemia/*TH; Male; Middle Age; Prospective Studies; Solutions. | Serum glucose changes after administration of 50% dextrose solution: pre- and in-hospital calculations. | JOURNAL ARTICLE. | A prospective clinical trial was conducted to estimate the rise in serum glucose level after an intravenous bolus of 50 ml of 50% dextrose solution (D-50) in the emergency department setting. Fifty one subjects with altered levels of consciousness were studied. Of these, 23 patients were known diabetics, and 28 were not diabetic. The change in glucose level for the total study group ranged from a low of 37 mg/dl to a high of 370 mg/dl, with a mean of 166 +/- 77 mg/dl. The mean for the diabetic and non-diabetic groups were 177 +/- 80 mg/dl and 154 +/- 75 mg/dl. These results suggest that serum glucose levels cannot be quantitatively predicted after a single intravenous bolus of D-50. | Adler PM. | Am J Emerg Med 8703; 4(6):504-6 |
1 | 87,049,092 | Aged; Aged, 80 and over; Case Report; Female; Human; Intubation, Gastrointestinal/*AE; Pneumothorax/*ET/RA/TH; Suicide, Attempted. | Nasogastric intubation: morbidity in an asymptomatic patient. | JOURNAL ARTICLE. | An unusual case of a misdirected nasogastric tube is described. An elderly woman was brought to an emergency department following intentional drug overdose. Initially unrecognized errant placement of a large-bore nasogastric tube resulted in tension pneumothorax, pneumonia, and subsequent death. Pertinent medical literature is reviewed, clinical considerations for the elderly patient are discussed, and suggestions for proper nasogastric tube placement are offered. | Gough D; Rust D. | Am J Emerg Med 8703; 4(6):511-3 |
1 | 87,049,093 | Abdominal Injuries/ET; Accidents, Occupational; Accidents, Traffic/*; Adult; Amputation; Blood Transfusion/*; Case Report; Female; Fractures/ET; Human; Pelvic Bones/IN; Shock, Hemorrhagic/ET/*TH; Wounds, Nonpenetrating/*CO. | Massive transfusion without major complications after trauma. | JOURNAL ARTICLE. | A case of massive degloving injury of the trunk, with open pelvic fracture, and evisceration of abdominal contents from blunt trauma is presented. The most significant aspect of this case was the transfusion of 173 units of packed cells and 176 units of fresh frozen plasma in the first thirty hours. The patient ultimately recovered and returned to work. | Brotman S; Lamonica C; Cowley RA. | Am J Emerg Med 8703; 4(6):514-5 |
1 | 87,049,094 | Adult; Carbon Monoxide Poisoning/CO/*TH; Female; Human; Labor; Pregnancy; Pregnancy Complications/*TH; Pregnancy Trimester, Third; Respiration, Artificial; Respiratory Distress Syndrome, Adult/ET/*TH. | Acute carbon monoxide poisoning during pregnancy. | JOURNAL ARTICLE. | The course of a pregnant patient at term who was acutely exposed to carbon monoxide is described. A review of the fetal-maternal carboxyhemoglobin relationships and the differences in fetal oxyhemoglobin physiology are used to explain the recommendation that pregnant women with carbon monoxide poisoning should receive 100% oxygen therapy for up to five times longer than is otherwise necessary. The role of hyperbaric oxygen therapy is considered. | Margulies JL. | Am J Emerg Med 8703; 4(6):516-9 |
1 | 87,049,096 | Case Report; Child, Preschool; Drug Administration Routes; Emergencies; Human; Male; Phenytoin/*AD/BL; Status Epilepticus/BL/*DT; Tibia. | Intraosseous infusion of phenytoin. | JOURNAL ARTICLE. | In the critically ill child, administration of fluids and medications via the intraosseous route often proves life-saving. The authors describe the case of a child with status epilepticus in whom phenytoin was administered via the intraosseous route, and seizure resolution and therapeutic serum levels were achieved. Intraosseous drug administration should be reserved for the rare critically ill child in whom vascular access proves impossible. | Walsh-Kelly CM; Berens RJ; Glaeser PW; Losek JD. | Am J Emerg Med 8703; 4(6):523-4 |
1 | 87,049,098 | Alcohol Drinking; Case Report; Emergencies; Esophageal Diseases/CO/*DI/SU; Human; Male; Middle Age; Rupture, Spontaneous; Syndrome; Vomiting/ET. | Boerhaave's syndrome: an elusive diagnosis. | JOURNAL ARTICLE. | Boerhaave's syndrome represents a diagnostic dilemma for the emergency physician. The prognosis of this truly life-threatening emergency is darkened by any significant diagnostic delay. Unfortunately, classic or expected symptoms and signs are frequently absent at presentation, a circumstance that leads to frequent misdiagnosis. Two cases of Boerhaave's syndrome with "atypical" clinical presentations are reviewed and discussed. It is clear that Boerhaave's syndrome should always be suspected in the evaluation of any sudden chest, abdominal, or back pain associated with emesis. However, emphasis should be placed on the fact that this entity may occur without emesis. The chest radiograph is the most helpful diagnostic aid. Undoubtedly, maintenance of a high degree of suspicion by the emergency physician for Boerhaave's syndrome will lead consistently to earlier diagnosis, and subsequent aggressive intervention should result in considerable reduction in rates of both morbidity and mortality. | Schwartz JA; Turnbull TL; Dymowski J; Uehara DT. | Am J Emerg Med 8703; 4(6):532-6 |
1 | 87,049,099 | Adult; Case Report; Electrocardiography/*; Extrasystole/*PP; Female; Human; Male; Middle Age; Tachycardia, Sinus/*PP; Tachycardia, Supraventricular/*PP. | Cases in electrocardiography. | JOURNAL ARTICLE. | Boerhaave's syndrome represents a diagnostic dilemma for the emergency physician. The prognosis of this truly life-threatening emergency is darkened by any significant diagnostic delay. Unfortunately, classic or expected symptoms and signs are frequently absent at presentation, a circumstance that leads to frequent misdiagnosis. Two cases of Boerhaave's syndrome with "atypical" clinical presentations are reviewed and discussed. It is clear that Boerhaave's syndrome should always be suspected in the evaluation of any sudden chest, abdominal, or back pain associated with emesis. However, emphasis should be placed on the fact that this entity may occur without emesis. The chest radiograph is the most helpful diagnostic aid. Undoubtedly, maintenance of a high degree of suspicion by the emergency physician for Boerhaave's syndrome will lead consistently to earlier diagnosis, and subsequent aggressive intervention should result in considerable reduction in rates of both morbidity and mortality. | Zimmers T. | Am J Emerg Med 8703; 4(6):537-9 |
1 | 87,049,100 | Bone Marrow; Child; Child, Preschool; Drug Administration Routes/IS/*MT; Human; Infant; Needles. | Intraosseous infusions: a usable technique. | JOURNAL ARTICLE. | Intraosseous infusions were widely used in pediatric patients during the 1930s and 1940s. Recent reports have re-introduced this concept and confirmed its safety and ready accessability for fluid and drug administration. However, these reports have not addressed the difficulties encountered during insertion of the intraosseous needle. Spinal needles, standard metal intravenous (IV) needles, and bone marrow biopsy needles have been suggested for intraosseous infusion. These needles were tested for ease of insertion on a pediatric cadaver leg. The site for needle placement was also evaluated during the study. It was found that the 13-gauge Kormed/Jamshidi disposable bone marrow/aspiration needle was the easiest to insert and did not plug with bone or tissue during insertion. An area proximal to the medial malleolus was found to provide a stable, relatively flat, and easily penetrable location for needle placement. This method was successfully utilized in ten pediatric and five adult patients. Intraosseous needle placement is a safe, rapid method to gain access to the venous circulation. By utilizing these techniques, a stable, usable fluid line can be established in even the most dehydrated pediatric patients. | Iserson KV; Criss E. | Am J Emerg Med 8703; 4(6):540-2 |
1 | 87,049,101 | Adult; Case Report; Cellulitis/CI; Human; Injections, Intravenous; Male; Pulmonary Edema/CI; Suicide, Attempted/*; Turpentine/*AD. | Intravenous hydrocarbon abuse. | JOURNAL ARTICLE. | The case of a man who injected turpentine intravenously in an attempt to kill himself is reported. The patient developed immediate pulmonary edema and hypoxia, followed later by cellulitis at the site of injection. Although only one death to date has been attributed to this form of chemical abuse, extensive local reactions, pulmonary involvement, central nervous system depression, and febrile reactions should be anticipated, and such patients should be admitted to the hospital. Patients should be observed for local reactions and myonecrosis around the site of injection, especially as these occur 12-24 hours later. | Wason S; Greiner PT. | Am J Emerg Med 8703; 4(6):543-4 |
1 | 87,049,102 | Abdomen; Administration, Inhalation; Adolescence; Adult; Alopecia/CI; Case Report; Cocaine/*; Drug Contamination; Human; Hypertension/CI; Male; Pain/CI; Substance Abuse/*; Thallium/*PO. | Thallium poisoning in cocaine abusers. | JOURNAL ARTICLE. | The users of illicit drugs is endangered by both unpredictable concentrations of the drugs and by unexpected adulterants that may be present. Cocaine has been adulterated or admixed with numerous substances, among them local anesthetics, amphetamine, phencyclidine, and strychnine. We report three cases of thallium poisoning following nasal insufflation of a substance that was believed to have been cocaine. | Insley BM; Grufferman S; Ayliffe HE. | Am J Emerg Med 8703; 4(6):545-8 |
1 | 87,049,103 | Adult; Case Report; Ethchlorvynol/*; Female; Human; Injections, Intravenous; Male; Pulmonary Edema/*CI; Substance Abuse/*. | Pulmonary edema induced by intravenous ethchlorvynol. | JOURNAL ARTICLE. | The intravenous injection of ethchlorvynol is an uncommon cause of noncardiac pulmonary edema. Two cases of intravenous ethchlorvynol-induced pulmonary edema are presented. The patients fell asleep after injecting the liquid contents of Placydil capsules (ethchlorvynol) and awoke several hours later with severe dyspnea. Arterial blood gases demonstrated marked hypoxia. Chest radiographs revealed bilateral diffuse alveolar densities. The patients' symptoms and radiographic findings resolved after several days of supportive care. Changes in the lung caused by ethchlorvynol may be the result of direct effect of the drug on the lung. | Conces DJ Jr; Kreipke DL; Tarver RD. | Am J Emerg Med 8703; 4(6):549-51 |
1 | 87,049,104 | Adolescence; Atropine/*TU; Baclofen/*PO; Bradycardia/CI/*DT; Case Report; Human; Hypotension/CI/*DT; Male. | Atropine in the treatment of baclofen overdose. | JOURNAL ARTICLE. | A patient suffering baclofen overdose successfully treated with atropine is reported. Three hours after admission for ingestion of at least 300 mg baclofen as a single dose, the patient became comatose and subsequently bradycardic, hypotensive, and hypothermic. A prompt increase in heart rate and blood pressure followed administration of 1 mg of atropine sulfate. Atropine appears to be useful in treating cases of baclofen overdose complicated by bradycardia and hypotension. | Cohen MB; Gailey RA; McCoy GC. | Am J Emerg Med 8703; 4(6):552-3 |
1 | 87,049,105 | Administration, Oral; Adolescence; Burns, Chemical/*ET; Case Report; Colloids; Epiglottis/*IN; Human; Male; Pharynx/*IN; Salicylic Acids/*AD; Suicide, Attempted/*; Tongue/*IN. | Ingestion of Compound W, an unusual caustic. | JOURNAL ARTICLE. | A case of an unusual caustic ingestion involving Compound W, an over the counter wart remover is presented. Chemical burns of the tongue, pharynx and larynx developed. The active ingredient in this preparation: salicylic acid in a flexible collodion vehicle produces caustic injury through a keratolytic action, which may be enhanced by the presence of collodion. | Sacchetti A; Ramoska E. | Am J Emerg Med 8703; 4(6):554-5 |
1 | 87,049,106 | Allied Health Personnel/*; Electric Countershock/*; Emergency Medical Technicians/*; Human; Lidocaine/TU; Recurrence; Ventricular Fibrillation/MO/*TH. | EMT-D fibrillation: more shocks for the future [editorial] | EDITORIAL. | A case of an unusual caustic ingestion involving Compound W, an over the counter wart remover is presented. Chemical burns of the tongue, pharynx and larynx developed. The active ingredient in this preparation: salicylic acid in a flexible collodion vehicle produces caustic injury through a keratolytic action, which may be enhanced by the presence of collodion. | Thompson BM. | Am J Emerg Med 8703; 4(6):570-1 |
1 | 87,049,107 | Adolescence; Child; Child, Preschool; Emergencies/*; Female; G Suits/*UT; Human; Male; Massachusetts; Retrospective Studies; Transportation of Patients. | Estimating prehospital demand for pediatric antishock garments. | JOURNAL ARTICLE. | A case of an unusual caustic ingestion involving Compound W, an over the counter wart remover is presented. Chemical burns of the tongue, pharynx and larynx developed. The active ingredient in this preparation: salicylic acid in a flexible collodion vehicle produces caustic injury through a keratolytic action, which may be enhanced by the presence of collodion. | McCabe CJ; Cadigan RT; Bugarin CE; Azzara CV. | Am J Emerg Med 8703; 4(6):572-4 |
1 | 87,049,108 | Emergency Service, Hospital/*; Human; Thoracic Injuries/*SU; Transportation of Patients/*MT; Wounds, Penetrating/*MO. | Emergency department thoracotomy [letter] | LETTER. | A case of an unusual caustic ingestion involving Compound W, an over the counter wart remover is presented. Chemical burns of the tongue, pharynx and larynx developed. The active ingredient in this preparation: salicylic acid in a flexible collodion vehicle produces caustic injury through a keratolytic action, which may be enhanced by the presence of collodion. | Hoffman JR. | Am J Emerg Med 8703; 4(6):574-5 |
1 | 87,049,109 | Adult; Career Choice/*; Emergency Medicine/*ED; Female; Goals; Human; Internship and Residency/*; Male. | Academic aspirations of residents. | JOURNAL ARTICLE. | A case of an unusual caustic ingestion involving Compound W, an over the counter wart remover is presented. Chemical burns of the tongue, pharynx and larynx developed. The active ingredient in this preparation: salicylic acid in a flexible collodion vehicle produces caustic injury through a keratolytic action, which may be enhanced by the presence of collodion. | Lundberg T; Hedges JR. | Am J Emerg Med 8703; 4(6):575-7 |
1 | 87,049,271 | Adult; Antithrombin III/BL; Blood Proteins/AN; Case Report; Female; Fibrinogen/AN; Heparin/*TU; Human; Hypercholesterolemia/BL/*TH; Lipoproteins, HDL Cholesterol/BL; Lipoproteins, LDL/*BL/IP; Lipoproteins, LDL Cholesterol/BL; Male; Middle Age; Plasma Volume; Plasminogen/AN; Precipitation. | Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application. | JOURNAL ARTICLE. | A case of an unusual caustic ingestion involving Compound W, an over the counter wart remover is presented. Chemical burns of the tongue, pharynx and larynx developed. The active ingredient in this preparation: salicylic acid in a flexible collodion vehicle produces caustic injury through a keratolytic action, which may be enhanced by the presence of collodion. | Eisenhauer T; Armstrong VW; Wieland H; Fuchs C; Nebendahl K; Scheler F; Seidel D. | ASAIO Trans 8703; 32(1):104-7 |
1 | 87,049,272 | Anaphylaxis; Cellulose/*AA/AN; Ethylene Oxide/AE/*AN; Hemodialysis/AE; Human; Kinetics; Membranes, Artificial/*; Sterilization. | Extractable ethylene oxide from cuprammonium cellulose plate dialyzers: importance of potting compound. | JOURNAL ARTICLE. | Our results suggest that ethylene oxide retention after sterilization is increased in cuprammonium cellulose plate dialyzers containing potting compound. In contrast, cuprammonium cellulose plate dialyzers without potting compound were characterized by a rapid disappearance of retained ethylene oxide after sterilization. Whether these findings explain the low incidence of SARD with cuprammonium cellulose plate dialyzers that do not contain potting material is a matter for continued study and experimentation. | Ing TS; Daugirdas JT. | ASAIO Trans 8703; 32(1):108-10 |
1 | 87,049,273 | Adult; Aged; Case Report; Comparative Study; Creatinine/ME; Female; Human; Kidney Failure, Chronic/*TH; Male; Middle Age; Peritoneal Dialysis/*; Peritoneal Dialysis, Continuous Ambulatory/*; Ultrafiltration; Urea/ME. | Peritoneal dialysis. | JOURNAL ARTICLE. | Our results suggest that ethylene oxide retention after sterilization is increased in cuprammonium cellulose plate dialyzers containing potting compound. In contrast, cuprammonium cellulose plate dialyzers without potting compound were characterized by a rapid disappearance of retained ethylene oxide after sterilization. Whether these findings explain the low incidence of SARD with cuprammonium cellulose plate dialyzers that do not contain potting material is a matter for continued study and experimentation. | Nolph KD; Twardowski ZJ; Khanna R. | ASAIO Trans 8703; 32(1):11-6 |
1 | 87,049,275 | Animal; Carotid Arteries/*TR/UL; Collagen/*AN; Compliance; Delayed-Action Preparations; Dogs; Heparin/AD/AN/*TU; Microscopy, Electron, Scanning. | Development of a small caliber vascular graft by a new crosslinking method incorporating slow heparin release collagen and natural tissue compliance. | JOURNAL ARTICLE. | Our results suggest that ethylene oxide retention after sterilization is increased in cuprammonium cellulose plate dialyzers containing potting compound. In contrast, cuprammonium cellulose plate dialyzers without potting compound were characterized by a rapid disappearance of retained ethylene oxide after sterilization. Whether these findings explain the low incidence of SARD with cuprammonium cellulose plate dialyzers that do not contain potting material is a matter for continued study and experimentation. | Noishiki Y; Miyata T; Kodaira K. | ASAIO Trans 8703; 32(1):114-9 |
1 | 87,049,276 | Adolescence; Adult; Aged; Aluminum/*TU; Antacids/AN/*TU; Hemodialysis/*; Human; Middle Age; Strontium/AN/*BL; Uremia/*BL/TH. | Strontium overload in uremic patients on regular dialytic treatment. | JOURNAL ARTICLE. | Our results suggest that ethylene oxide retention after sterilization is increased in cuprammonium cellulose plate dialyzers containing potting compound. In contrast, cuprammonium cellulose plate dialyzers without potting compound were characterized by a rapid disappearance of retained ethylene oxide after sterilization. Whether these findings explain the low incidence of SARD with cuprammonium cellulose plate dialyzers that do not contain potting material is a matter for continued study and experimentation. | Canavese C; Pacitti A; Salomone M; Santoro MA; Stratta P; Mangiarotti G; Talarico S; Sabbioni E; Pietra R; Vercellone A. | ASAIO Trans 8703; 32(1):120-2 |
1 | 87,049,277 | Cellulose/AA; Human; Kidney Failure, Acute/TH; Kidney Failure, Chronic/TH; Kidney, Artificial/*; Membranes, Artificial; Prosthesis Design; Uremia/TH. | A bag-filter model of a new pret a porter artificial kidney. | JOURNAL ARTICLE. | Our results suggest that ethylene oxide retention after sterilization is increased in cuprammonium cellulose plate dialyzers containing potting compound. In contrast, cuprammonium cellulose plate dialyzers without potting compound were characterized by a rapid disappearance of retained ethylene oxide after sterilization. Whether these findings explain the low incidence of SARD with cuprammonium cellulose plate dialyzers that do not contain potting material is a matter for continued study and experimentation. | Bazzato G; Coli U; Landini S; Fracasso A; Morachiello P; Righetto F; Scanferla F. | ASAIO Trans 8703; 32(1):123-6 |
1 | 87,049,278 | Calcium/BL; Calcium Carbonate/*TU; Female; Hemodialysis/*MT; Human; Kidney Failure, Chronic/BL/*TH; Male; Phosphates/*ME; Phosphorus/BL. | Calcium carbonate as a phosphate binder in hemodialysis patients. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Taber TE; Hegemen TF; York S. | ASAIO Trans 8703; 32(1):127-9 |
1 | 87,049,279 | Animal; Artificial Organs; Capsules; Endocrine Glands/*TR; Peritoneal Cavity/*SU; Rats; Rats, Inbred Strains. | An intraperitoneal receptacle for macroencapsulated endocrine tissue. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Aebischer P; Panol G; Galletti PM. | ASAIO Trans 8703; 32(1):130-3 |
1 | 87,049,280 | Animal; Artificial Organs/*; Hypocalcemia/*TH; Microscopy, Electron; Parathyroid Glands/CY/*TR/UL; Peritoneal Cavity; Rats; Rats, Inbred Strains. | A bioartificial parathyroid. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Aebischer P; Russell PC; Christenson L; Panol G; Monchik JM; Galletti PM. | ASAIO Trans 8703; 32(1):134-7 |
1 | 87,049,281 | Adult; Bilirubin/BL; Female; Fluorescence; Human; Hyperbilirubinemia/ET/*TH; Liver Diseases/*TH; Male; Middle Age; Phototherapy/*; Plasma/*/RE. | Innovation in blood purification for hepatic failure: direct photoirradiation of plasma. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Totsune K. | ASAIO Trans 8703; 32(1):138-42 |
1 | 87,049,282 | Human; Membranes, Artificial/*; Middle Ear Ventilation/*/IS; Oxygen; Permeability. | Permeation rate to oxygen of membrane tympanostomy tubes. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Rodgers VG; Borovetz HS. | ASAIO Trans 8703; 32(1):143-4 |
1 | 87,049,284 | Animal; Blood Glucose/*AN; Dogs; Electrodes; Insulin Infusion Systems/*; Prosthesis Design; Rabbits; Support, U.S. Gov't, P.H.S.. | Short-term in vivo operation of a glucose sensor. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Gough DA; Armour JC; Lucisano JY; McKean BD. | ASAIO Trans 8703; 32(1):148-50 |
1 | 87,049,285 | Adhesiveness; Animal; Dogs; Elasticity; Human; Rubber/*; Stress, Mechanical; Surgery; Tissue Adhesives/*. | A novel elastomeric surgical adhesive: design, properties, and in vivo performances. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Matsuda T; Itoh T; Yamaguchi T; Iwata H; Hayashi K; Uemura S; Ando T; Adachi S; Nakajima N. | ASAIO Trans 8703; 32(1):151-6 |
1 | 87,049,286 | Acrylic Resins/*; Electrochemistry; Implants, Artificial/*; Kinetics; Muscle Contraction; Muscles/PH; Povidone/*. | Contractile behavior of electrically activated mechanochemical polymer actuators. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | De Rossi DE; Chiarelli P; Buzzigoli G; Domenici C; Lazzeri L. | ASAIO Trans 8703; 32(1):157-62 |
1 | 87,049,287 | Animal; Aorta/PA; Blood Pressure; Cholesterol/BL; Heart Rate; Hypercholesterolemia/PA/PP/*TH; Male; Plasmapheresis/*; Rabbits; Regional Blood Flow. | Long-term repetitive plasmapheresis in hypercholesterolemic rabbits. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Kutsumi Y; Fujiwara R; Tamai T; Takai H; Nakai T; Miyabo S. | ASAIO Trans 8703; 32(1):163-7 |
1 | 87,049,289 | Adolescence; Adult; Bicarbonates/*TU; Child; Evaluation Studies; Follow-Up Studies; Hemodialysis/*/AE/MT; Hospitalization; Human; Middle Age; Morbidity; Risk; Time Factors; Uremia/PP/TH. | Rapid high-efficiency bicarbonate hemodialysis. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Keshaviah P; Collins A. | ASAIO Trans 8703; 32(1):17-23 |
1 | 87,049,290 | Aged; Aluminum/BL/*PO; Case Report; Diabetic Nephropathies/TH; Encephalitis/*CI; Female; Hemodialysis/*AE; Human; Kidney Failure, Chronic/ET/*TH; Male; Middle Age; Nephrotic Syndrome/CO/*TH; Uremia/*TH. | Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. | JOURNAL ARTICLE. | Calcium carbonate appears to be as effective as aluminum hydroxide in binding dietary phosphorus in hemodialysis patients. The long-term safety of this medication appears acceptable in view of today's therapeutic options. | Bakir AA; Hryhorczuk DO; Berman E; Dunea G. | ASAIO Trans 8703; 32(1):171-6 |
1 | 87,049,292 | Animal; Arteries/ME/*SU; Collagen/BI; Dogs; Hydroxyproline/BI; Laser Surgery/*; Support, U.S. Gov't, P.H.S.; Tensile Strength; Veins/ME/*SU. | Laser welding of large diameter arteries and veins. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | White RA; Kopchok G; Donayre C; Lyons R; White G; Klein SR; Abergel RP; Uitto J. | ASAIO Trans 8703; 32(1):181-3 |
1 | 87,049,293 | Aspirin/*PD; Blood Platelets/DE; Cell Division/DE; Cells, Cultured; Dipyridamole/*PD; Endothelium/*CY/DE; Human; Ibuprofen/*PD; Kinetics; Umbilical Veins. | Effect of antiplatelet drugs on human endothelial cell growth in tissue culture. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Evans DK; Campbell J; Herring M; Glover J. | ASAIO Trans 8703; 32(1):184-6 |
1 | 87,049,294 | Animal; Blood Platelets/*PH; Blood Vessel Prosthesis/*; Dogs; Femoral Artery/*SU; Femoral Vein/DE/*TR; Fibrinogen/*PH; Indium/DU; Iodine Radioisotopes/DU; Polytetrafluoroethylene/*; Radioisotopes/DU; Support, U.S. Gov't, P.H.S.; Thrombosis/*PP; Tropolone/AA/DU; Vitamin E/BL/*PD. | Quantitation of platelet and fibrinogen deposition on PTFE and vein grafts in dogs and the effect of vitamin E on graft thrombosis in the acute phase. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Dewanjee MK; Solis E; Mackey ST; Gonzales G; Chesebro JH; Kaye MP. | ASAIO Trans 8703; 32(1):187-92 |
1 | 87,049,295 | Animal; Biocompatible Materials/*; Blood Vessel Prosthesis/*; Dogs; Microscopy, Electron, Scanning; Polyurethanes/*; Silicones/*; Siloxanes/*; Surface Properties; Thrombosis/*PC. | Evaluation of a new antithrombogenic polyurethane-polysiloxane complex biomaterial. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Ohkubo N; Hirose H; Matsuda H; Nakano S; Shirakura R; Maeda S; Ohtani M; Yoda R; Kawashima Y. | ASAIO Trans 8703; 32(1):193-7 |
1 | 87,049,296 | Adult; Aluminum/*AE; Case Report; Deferoxamine/*TU; Fractures/*DT/ET; Hemodialysis/*AE; Human; Humeral Fractures/DT/ET; Humerus/RA; Kidney Failure, Chronic/TH; Male; Osteomalacia/CI/*CO; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.; Wound Healing/*DE. | Fracture healing with deferoxamine therapy in a patient with aluminum-associated osteomalacia. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Phelps KR; Einhorn TA; Vigorita VJ; Lundin AP; Friedman EA. | ASAIO Trans 8703; 32(1):198-200 |
1 | 87,049,297 | Animal; Assisted Circulation/*; Dogs; Electrocardiography; Heart-Assist Devices/*; Myocardial Infarction/PP/*TH; Nuclear Magnetic Resonance/DU/IS/MT. | Therapeutic effect of a left ventricular assist device on acute myocardial infarction evaluated by magnetic resonance imaging. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Nakatani T; Takano H; Noda H; Fukuda S; Nishimura T; Yamada Y; Kozuka T; Akutsu T. | ASAIO Trans 8703; 32(1):201-6 |
1 | 87,049,298 | Animal; Cattle; Cerebrovascular Disorders/ET; Comparative Study; Heart, Artificial/*/AE; Human; Prosthesis Design; Sheep; Support, Non-U.S. Gov't; Support, U.S. Gov't, P.H.S.. | Comparison of clinical and animal recipients of a pneumatic artificial heart. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Taenaka Y; Olsen DB; Riebman JB; Burns GB; Crump CL. | ASAIO Trans 8703; 32(1):207-10 |
1 | 87,049,299 | Angioplasty, Transluminal/AE/*IS/MT; Animal; Dogs; Heart Failure, Congestive/ET/PP/*TH; Heart-Assist Devices; Hemodynamics. | Experimental evaluation of extrapulmonary arterial balloon pumping (EPABP) for right heart failure of diverse etiologies. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Miya J; Maeta H; Asakura T; Hori M. | ASAIO Trans 8703; 32(1):211-6 |
1 | 87,049,300 | Animal; Aorta/SU; Assisted Circulation/*; Cardiac Output; Coronary Circulation; Dogs; Heart/PP; Heart Atrium/SU; Heart-Assist Devices/*; Myocardial Infarction/PP/*TH. | The effect of left ventricular assistance on the area of infarcted myocardium. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Wei CM; Yada I; Kusagawa M. | ASAIO Trans 8703; 32(1):217-20 |
1 | 87,049,301 | Cardiac Output; Emergencies/*; Heart, Artificial/*AE; Human; Hypertension, Pulmonary/ET/TH; Monitoring, Physiologic. | Drive system management of emergency conditions in three permanent total artificial heart patients. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Mays JB; Hastings WL; Williams MA; Barker LE; DeVries WC. | ASAIO Trans 8703; 32(1):221-5 |
1 | 87,049,304 | Allylamine; Animal; Chronic Disease; Disease Models, Animal; Echocardiography; Heart/DE; Heart Failure, Congestive/CI/PA/*PP; Microscopy, Electron; Myocardium/PA/UL; Sheep; Support, U.S. Gov't, P.H.S.. | Large-animal model of chronic congestive heart failure induced by intracoronary allylamine. | JOURNAL ARTICLE. | Based on our preliminary studies and the results of this study, we conclude that argon laser welding of 4-8 mm internal diameter veins, arteries, and arteriovenous fistulas may have several potential advantages compared to conventional suture techniques. The benefits of laser repairs may include improved mechanical properties, and absence of the foreign body response related to sutures. Laser welding is sterile, nontactile and possibly time conserving, and the wounds heal rapidly without aneurysms or excess tissue proliferation. | Beck LS; Strickland RD; Bagley BL; Mortensen JD; Hammond ME; Ashton AH; Head DR; Braun MR; Weiler MJ. | ASAIO Trans 8703; 32(1):238-41 |
1 | 87,049,306 | Animal; Assisted Circulation/*; Blood Chemical Analysis; Body Temperature; Cattle; Evaluation Studies; Heart-Assist Devices/*; Human; Implants, Artificial; Prosthesis Design; Respiration; Support, U.S. Gov't, P.H.S.. | In vivo evaluation of a permanently implantable thermal ventricular assist system. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Sugita Y; Navarro RR; White M; Whalen R; Kiraly RJ; Harasaki H; Nose Y. | ASAIO Trans 8703; 32(1):242-7 |
1 | 87,049,307 | Animal; Chronic Disease; Disease Models, Animal; Dogs; Heart/*PP; Heart Failure, Congestive/PA/*PP; Heart Ventricle/PP; Myocardium/*PA; Support, U.S. Gov't, P.H.S.. | Experimental chronic left ventricular failure in the dog. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Hagiwara K; Freed PS; Wasfie T; Bar-Lev A; Mandell G; Cardona R; Stein PD; Sabbah HN; Kantrowitz A. | ASAIO Trans 8703; 32(1):248-52 |
1 | 87,049,309 | Comparative Study; Evaluation Studies; Heart/PH/PP; Heart, Artificial/*; Human; Microcomputers; Prosthesis Design; Support, Non-U.S. Gov't; Ultrasonics. | Instrumentation for deriving pneumatic TAH control signals from the driveline pressure and flow. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Wurzel D; Wildevuur W; Kolff J. | ASAIO Trans 8703; 32(1):258-62 |
1 | 87,049,310 | Animal; Arterioles/PA; Assisted Circulation/*; Cattle; Heart/*PP; Heart Ventricle/PP; Heart-Assist Devices/*; Hemodynamics; Prosthesis Design; Pulse; Regional Blood Flow; Renal Circulation; Support, Non-U.S. Gov't. | Idioperipheral pulsation during nonpulsatile biventricular bypass experiments. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Tsutsui T; Sutton C; Harasaki H; Jacobs G; Golding L; Nose Y. | ASAIO Trans 8703; 32(1):263-8 |
1 | 87,049,311 | Assisted Circulation/*/AE; Beta-Thromboglobulin/AN; Blood Coagulation; Blood Platelets/PH; Heart-Assist Devices/*/AE; Human; Lactate Dehydrogenase/BL; Prosthesis Design; Stress, Mechanical. | Investigation of the flow in a centrifugal blood pump. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Affeld K; Schichl K; Yoganathan A. | ASAIO Trans 8703; 32(1):269-73 |
1 | 87,049,312 | Analysis of Variance; Azure Stains; Extracorporeal Circulation/*; Heparin/*BL; Human; Regression Analysis; Stains and Staining. | Rapid assay for heparin during extracorporeal circulation. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Ross RL; Whittlesey GC; Splittgerber FH; Salley SO; Klein MD. | ASAIO Trans 8703; 32(1):274-7 |
1 | 87,049,313 | Animal; Blood Pressure/*; Heart Surgery/*; Heart Ventricle/SU; Myocardial Contraction/*; Support, U.S. Gov't, P.H.S.; Swine; Systole/*. | Right ventricular end-systolic pressure-dimension relationship during left ventricular bypass in anesthetized pigs. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Farrar DJ; Compton PG; Verderber A; Hill JD. | ASAIO Trans 8703; 32(1):278-81 |
1 | 87,049,314 | Bioprosthesis/*ST; Heart Valve Prosthesis/*ST; Human; Prosthesis Design; Quality Control; Stress, Mechanical. | Mechanical factors influencing the durability of heart valve pericardial bioprostheses. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Gabbay S; Bortolotti U; Josif M. | ASAIO Trans 8703; 32(1):282-7 |
1 | 87,049,317 | Animal; Arteriovenous Shunt, Surgical/*/AE; Dogs; Hemodialysis/AE/*MT; Kidney, Artificial/*; Perfusion; Polytetrafluoroethylene/*; Prosthesis Design; Silicones/*; Support, Non-U.S. Gov't; Thrombosis/ET. | PTFE-silicone self-sealing dialysis prosthesis. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Schanzer H; Martinelli GP; Bock G; Peirce EC 2d. | ASAIO Trans 8703; 32(1):297-9 |
1 | 87,049,318 | Alloys/*; Animal; Anticoagulants/TU; Blood Pressure; Blood Vessel Prosthesis/*; Dogs; Monitoring, Physiologic; Prosthesis Design; Support, Non-U.S. Gov't. | Nonsurgical implantation of a vascular ring prosthesis using thermal shape memory Ti/Ni alloy (Nitinol wire). | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Sugita Y; Shimomitsu T; Oku T; Murabayashi S; Kambic HE; Harasaki H; Shirey E; Golding L; Nose Y. | ASAIO Trans 8703; 32(1):30-4 |
1 | 87,049,319 | Female; Follow-Up Studies; Hematocrit; Hemodialysis/*MT; Human; Kidney, Artificial; Kinetics; Male; Middle Age; Urea/ME. | Long-term experience with routine single-needle dialysis. A review. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Vanholder R; Hoenich N; Bogaert AM; Ringoir S. | ASAIO Trans 8703; 32(1):300-4 |
1 | 87,049,320 | Anemia/*ET; Female; Hemodialysis/*/AE; Human; Kidney Failure, Chronic/BL/*TH; Male; Manganese/BL; Middle Age; Nickel/BL; Trace Elements/*BL; Zinc/BL. | Trace metals and anemia in chronic hemodialysis patients. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Hosokawa S; Nishitani H; Tomoyoshi T; Yoshida O. | ASAIO Trans 8703; 32(1):305-8 |
1 | 87,049,321 | Animal; Blood Vessel Prosthesis/*; Comparative Study; Dogs; Endothelium/CY/UL; Evaluation Studies; Female; Male; Microscopy, Electron, Scanning/MT; Polyesters/*. | Evaluation of a new vascular graft prosthesis fabricated from ultrafine polyester fiber. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Noishiki Y; Watanabe K; Okamoto M; Kikuchi Y; Mori Y. | ASAIO Trans 8703; 32(1):309-14 |
1 | 87,049,323 | Blood Coagulation/*DE; Blood Coagulation Tests; Fibrinolysis/*DE; Human; Kinetics; Microscopy, Electron, Scanning; Polymethacrylic Acids/*PD. | Effect of a hydrogel with long polyethyleneoxide chains on blood coagulation and fibrinolysis. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Nakao A; Ohkura K; Nonami T; Harada A; Takagi H; Mori Y. | ASAIO Trans 8703; 32(1):319-22 |
1 | 87,049,324 | Adsorption; Blood Coagulation/*DE; Blood Coagulation Factors/*ME; Blood Proteins/*ME; Human; IgG/*; Platelet Adhesiveness/*DE; Polyurethanes/*PD; Serum Albumin/*; Support, U.S. Gov't, P.H.S.. | Reduced platelet adhesion and activation of coagulation factors on polyurethane treated with albumin-IgG complex. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Mohammad SF; Olsen DB. | ASAIO Trans 8703; 32(1):323-6 |
1 | 87,049,325 | Animal; Aorta/*RE/UL; Coronary Vessels/*RE/UL; Dose-Response Relationship, Radiation; Heat; Human; Lasers/*; Microscopy, Electron; Rabbits; Ultraviolet Rays/*. | Thermal effects of far ultraviolet excimer laser radiation on biologic tissue. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Wollenek G; Laufer G. | ASAIO Trans 8703; 32(1):327-9 |
1 | 87,049,326 | Animal; Cattle; Erythrocytes/UL; Hemoglobins/AN; Hemolysis/*; Mathematics; Membranes, Artificial; Microscopy, Electron, Scanning; Models, Theoretical; Plasmapheresis/*; Pressure. | A model of hemolysis in membrane plasmapheresis. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Ding LH; Jaffrin MY; Gupta BB. | ASAIO Trans 8703; 32(1):330-3 |
1 | 87,049,327 | Adult; Animal; Blood Vessel Prosthesis/*; Cell Survival; Cells, Cultured; Comparative Study; Cross-Linking Reagents/*; Culture Media; Dogs; Endothelium/*CY; Female; Fibronectins/*; Human; Polyesters; Polytetrafluoroethylene; Pregnancy; Species Specificity; Umbilical Veins; Veins. | Fluid shear disruption of cultured endothelium: the effect of cell species, fibronectin cross-linking and supporting polymer. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Lundgren CH; Herring MB; Arnold MP; Glover JL; Bendick PJ. | ASAIO Trans 8703; 32(1):334-8 |
1 | 87,049,329 | Animal; Biocompatible Materials/*; Capsules; Chromatography, Gel; Collagen; Drug Screening; Implants, Artificial/*; Lactates/ME; Polymers/ME; Time Factors. | Tissue developed around bioresorbable implants. Load-bearing versus histology. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Richardson PD; Sasken H; Parhizgar A; Aebischer P; Panol G; Chiu TH; Galletti PM. | ASAIO Trans 8703; 32(1):342-5 |
1 | 87,049,335 | Animal; Biocompatible Materials; Catheters, Indwelling/*; Comparative Study; Diabetes Mellitus, Experimental/*DT; Dogs; Insulin Infusion Systems/*; Polyethylenes/*; Silicone Elastomers/*. | Use of polyethylene-lined silicone rubber cannulae in long-term insulin infusion in the dog. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Wigness BD; Rohde TD; Dorman FD; Buchwald H. | ASAIO Trans 8703; 32(1):363-6 |
1 | 87,049,336 | Adult; Aluminum/*BL/IP; Case Report; Chromatography, Gel/MT; Deferoxamine/AD/*BL/IP; Female; Hemodialysis/*; Human; Infusions, Intravenous; Male; Middle Age; Molecular Weight; Uremia/*BL/TH. | Chromatographic studies of aluminum-desferrioxamine complex in uremic patients. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Canavese C; Pacitti A; Salomone M; Pramotton C; Segoloni G; Bedino S; Testore G; Lamon S; Vercellone A. | ASAIO Trans 8703; 32(1):367-9 |
1 | 87,049,337 | Adult; Aged; Aluminum/*TU; Blood/*; Female; Follow-Up Studies; Hematocrit; Hemodialysis/*; Human; Kidney Failure, Chronic/*BL/TH; Male; Middle Age; Phosphates/*BL; Support, Non-U.S. Gov't; Ultrafiltration/*. | Reduction in aluminum load after one year of hemodiafiltration. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Ahmad S; Vizzo JE; Scribner BH. | ASAIO Trans 8703; 32(1):370-3 |
1 | 87,049,338 | Adult; Aged; Blood Chemical Analysis; Female; Follow-Up Studies; Hemodialysis/*MT; Human; Kidney Failure, Chronic/BL/TH; Male; Middle Age; Support, Non-U.S. Gov't; Time Factors. | Short hemodialysis--10-year follow-up. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Raja R; Kramer M; Goldstein S; Caruana R; Lerner A. | ASAIO Trans 8703; 32(1):374-6 |
1 | 87,049,339 | Adult; Aged; Hemodialysis/*MT; Human; Kidney Failure, Chronic/*PP/TH; Middle Age; Nutritional Status/*; Parathyroid Hormones/BL; Serum Albumin/AN; Time Factors; Uremia/*PP/TH. | Rapid blood flow short dialysis does not adversely affect clinical, biochemical, or nutritional status of patients. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Rubin JE; Friedmann P; Berlyne GM. | ASAIO Trans 8703; 32(1):377-8 |
1 | 87,049,341 | Blood/*; Dextrans; Human; Kidney, Artificial/*; Molecular Weight; Structure-Activity Relationship; Support, U.S. Gov't, Non-P.H.S.; Ultrafiltration/*. | Macromolecular charge affects hemofilter solute sieving. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Leypoldt JK; Frigon RP; Henderson LW. | ASAIO Trans 8703; 32(1):384-7 |
1 | 87,049,342 | Human; Hypercholesterolemia, Familial/BL/*TH; Lipoproteins, LDL/*BL/IP; Microscopy, Electron, Scanning; Plasmapheresis/IS/*MT; Temperature; Ultrafiltration/IS/MT. | Comparison of plasmafractionation filters and filtration techniques in the clinical practice of LDL-apheresis. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Kochinke F; Baeyer HV; Schwaner I; Schwerdtfeger R. | ASAIO Trans 8703; 32(1):388-91 |
1 | 87,049,345 | Animal; Blood/*; Cattle; Electrolytes/BL; Membranes, Artificial/*; Microscopy, Electron, Scanning; Permeability; Polytetrafluoroethylene/*; Water. | Extraction of solute-free water from blood by membrane distillation. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Sakai K; Muroi T; Ozawa K; Takesawa S; Tamura M; Nakane T. | ASAIO Trans 8703; 32(1):397-400 |
1 | 87,049,346 | Adult; Aged; Blood/*; Burns/PP/*TH; Catheters, Indwelling; Edema/ET/*TH; Female; Heparin/TU; Human; Kidney Failure, Acute/ET/*TH; Male; Middle Age; Ultrafiltration/*. | Continuous arteriovenous hemofiltration for the treatment of anasarca and acute renal failure in severely burned patients. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Hubsher J; Olshan AR; Schwartz AB; Zoranski B; DeClement F; Bendlin A; Hensell D; Brezin JH; Krevolin LE; Chinitz JL. | ASAIO Trans 8703; 32(1):401-4 |
1 | 87,049,347 | Blood Component Removal/*IS/MT; Disposable Equipment; Erythrocyte Count; Hematocrit; Human; Leukocyte Count; Membranes, Artificial; Plasma/*; Platelet Count; Polyethylenes. | An automated plasma collector with innovative membrane and cassette-like disposable set. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Yamazaki Z; Kanai F; Hiraishi M; Ohnishi K; Idezuki Y; Takahama T; Fujimori Y; Asano K; Inoue N; Shibata Y; et al. | ASAIO Trans 8703; 32(1):405-9 |
1 | 87,049,348 | Animal; Blood Component Removal/*IS/MT; Cattle; Ceramics/*; Filtration; Hematocrit; Membranes, Artificial/*; Plasma/*; Support, Non-U.S. Gov't. | Design of a plasma separator using ceramic membranes. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Sakurai H; Ozawa K; Takesawa S; Sakai K. | ASAIO Trans 8703; 32(1):410-3 |
1 | 87,049,349 | Assisted Circulation/*; Blood/*; Cardiopulmonary Bypass; Creatinine/ME; Female; Heart Surgery; Heart-Assist Devices/*; Human; Intra-Aortic Balloon Pumping/*; Kidney Failure, Acute/ET/*TH; Male; Middle Age; Postoperative Complications/*TH; Ultrafiltration/*. | Continuous renal replacement therapy in patients with acute renal dysfunction undergoing intraaortic balloon pump and/or left ventricular device support. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Paganini EP; Suhoza K; Swann S; Golding L; Nakamoto S. | ASAIO Trans 8703; 32(1):414-7 |
1 | 87,049,350 | Filtration; Human; Mathematics; Membranes, Artificial; Plasmapheresis/*MT. | Relationship between Staverman's reflection and sieving coefficients in a plasma fractionator. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Mineshima M; Hasuo Y; Kaneko I; Era K; Agishi T; Ota K; Sakai K. | ASAIO Trans 8703; 32(1):418-21 |
1 | 87,049,351 | Evaluation Studies; Foreign Bodies/*PA; Heart, Artificial/*/AE; Human; Skin/*PA; Support, U.S. Gov't, P.H.S.; Time Factors. | The microscopic evaluation of skin buttons used in a long-term human total artificial heart recipient. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Murray KD; Abbott T; DeVries WC; Gaykowski R; Olsen DB. | ASAIO Trans 8703; 32(1):42-5 |
1 | 87,049,353 | Adsorption; Biocompatible Materials; Blood Proteins/*IP; Charcoal/*; Hemodialysis/*; Hemoperfusion/*; Human; Kidney Failure, Chronic/TH; Molecular Weight; Polyurethanes. | Elimination of low molecular weight proteins during hemoperfusion of dialysis patients using a urethane-sheet embedded with powdered charcoal. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Kawanishi H; Tsuchiya T; Sugiyama M; Nishiki M; Dohi K. | ASAIO Trans 8703; 32(1):425-8 |
1 | 87,049,354 | Animal; Biocompatible Materials; Blood Component Removal/*/IS/MT; Dextrans; Dogs; Filtration/MT; Human; Hypercholesterolemia/BL/TH; Membranes, Artificial; Molecular Weight; Plasma/*; Support, Non-U.S. Gov't. | Effect of plasma solute-membrane interaction on mean pore diameter. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Horiuchi T; Malchesky PS; Usami M; Emura M; Nose Y. | ASAIO Trans 8703; 32(1):429-34 |
1 | 87,049,357 | Animal; Ceramics/*; Comparative Study; Heart Valve Prosthesis/*; Materials Testing/*; Sheep; Support, Non-U.S. Gov't; Venae Cavae/PH. | Development of a fine ceramic heart valve for use as a cardiac prosthesis. | JOURNAL ARTICLE. | The System 7 pump/actuator/engine combination has demonstrated biologic compatibility and physiologic effectiveness and responsiveness in five TVAS in vivo studies. The recent 75-day implant supports the feasibility of extended reliability of the system components. Postoperative system maintenance was necessary only because of the nonhermetic design of System 7. However, the ability to pump 11 l/min at 120 beats/min, synchronize at beat rates of 144 beats/min, and pump against mean arterial pressures of more than 150 mmHg while maintaining hematologic and biochemical values within physiologic range sets a very optimistic stage for System 8 hardware. A System 8 concept is shown in Figure 14. The System 8 hardware will include a thermal salt package capable of providing completely untethered circulatory support for a nominal 8-h period. Recharge will be accomplished with a transcutaneous transformer in 1 h. Thermal management problems become minimal, with an average energy input of 15.8 W (peak of 24.9 W). The human preclinical testing of System 8 will start in 1988. | Mitamura Y; Mikami T; Yuta T; Matsumoto T; Shimooka T; Okamoto E; Eizuka N; Yamaguchi K. | ASAIO Trans 8703; 32(1):444-8 |
1 | 87,049,360 | Animal; Assisted Circulation/*IS; Cattle; Heart Rate; Heart-Assist Devices/*IS/MT; Hemoglobins/AN; Male; Postoperative Care; Support, Non-U.S. Gov't; Time Factors. | Roller screw electric motor ventricular assist device. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Richenbacher WE; Pae WE Jr; Magovern JA; Rosenberg G; Snyder AJ; Pierce WS. | ASAIO Trans 8703; 32(1):46-8 |
1 | 87,049,361 | Adult; Aged; Assisted Circulation/*; Case Report; Child, Preschool; Echocardiography/*; Female; Heart/*PP; Heart Surgery/*; Heart-Assist Devices/*; Hemodynamics; Human; Male; Middle Age; Monitoring, Physiologic/*; Postoperative Complications/TH. | Natural heart recovery under left ventricular assist device pumping studied by echocardiography. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Nakatani T; Takano H; Beppu S; Noda H; Fukuda S; Fujita T; Akutsu T; Nimura Y; Manabe H. | ASAIO Trans 8703; 32(1):461-6 |
1 | 87,049,363 | Animal; Axons/UL; Collagen/PH; Extracellular Matrix/*PH; Female; Glycoproteins/PH; Heparitin Sulfate/PH; Implants, Artificial/*; Laminin/PH; Membranes, Artificial; Mice; Microscopy, Electron; Myelin Sheath/UL; Nerve Regeneration/*; Sciatic Nerve/CY/*PH/UL. | Regeneration of transected sciatic nerves through semi-permeable nerve guidance channels. Effects of extracellular matrix protein additives. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Aebischer P; Valentini RF; Winn SR; Kunz S; Sasken H; Galletti PM. | ASAIO Trans 8703; 32(1):474-7 |
1 | 87,049,365 | Animal; Antibody Formation; Drug Hypersensitivity/*; Ethylene Oxide/*TO; Female; Hemodialysis; Human; IgE/AN; Male; Mice; Mice, Inbred Strains; Passive Cutaneous Anaphylaxis/*; Rats; Rats, Inbred Strains. | Animal model for ethylene oxide (EtO) associated hypersensitivity reactions. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Chapman J; Lee W; Youkilis E; Martis L. | ASAIO Trans 8703; 32(1):482-5 |
1 | 87,049,366 | Adolescence; Aged; Blood Proteins/AN; Case Report; Chronic Disease; Complement/AN; Demyelinating Diseases/*TH; Female; Follow-Up Studies; Human; Immunoglobulins/AN; Inflammation; Male; Plasma/*; Polyradiculoneuritis/*TH; Ultrafiltration/*/IS/MT. | Treatment of chronic inflammatory demyelinating polyradiculoneuropathy by plasma filtration. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Abe Y; Baba M; Baba T; Tamasawa N; Kurahashi K; Hirai Y; Nakahata H; Matsunaga M; Takebe K. | ASAIO Trans 8703; 32(1):486-9 |
1 | 87,049,367 | Aged; Blood/*; Heparin/TU; Human; Middle Age; Suction; Support, Non-U.S. Gov't; Ultrafiltration/*MT; Urea/BL; Vacuum. | Clinical trials with predilution and vacuum suction: enhancing the efficiency of the CAVH treatment. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Kaplan AA. | ASAIO Trans 8703; 32(1):49-51 |
1 | 87,049,368 | Alanine Aminotransferase/BL; Animal; Aspartate Aminotransferase/BL; Blood Coagulation Tests; Creatinine/BL; Dogs; Electrolytes/BL; Erythrocyte Count; Erythrocytes/AN; Exchange Transfusion, Whole Blood/*; Hematocrit/*; Hemoglobins/*/*AN; Platelet Count; Polyethylene Glycols/*; Solutions; Support, Non-U.S. Gov't; Urea/BL. | Physiologic effects of pyridoxalated-hemoglobin-polyethylene glycol conjugate solution in exchange transfusion. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Matsushita M; Iwashita Y; Iwasaki K; Ohki H; Nasu M; Horiuchi T; Chen JF; Goldcamp J; Murabayashi S; Harasaki H; et al. | ASAIO Trans 8703; 32(1):490-4 |
1 | 87,049,369 | Aged; Blood/*; Blood Proteins/AN; Case Report; Cryoglobulins/*IP/ME; Female; Human; Immunoglobulins/AN; Sjogren's Syndrome/BL/*TH; Ultrafiltration/*/IS/MT. | Clinical evaluation of a multilayered cryofilter for highly selective cryoglobulin removal. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Emura M; Horiuchi T; Malchesky PS; Goldcamp JB; Usami M; Sakamoto H; Matsushita M; Suzuki M; Nose Y. | ASAIO Trans 8703; 32(1):495-9 |
1 | 87,049,371 | Blood Pressure; Catheters, Indwelling/*ST; Hemodialysis/*ST; Human; Kidney Failure, Acute/*PP/TH; Kidney Failure, Chronic/*PP/TH; Polyurethanes; Quality Control; Support, Non-U.S. Gov't. | Minimum performance standards for double-lumen subclavian cannulas for hemodialysis. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Bregman H; Miller K; Berry L. | ASAIO Trans 8703; 32(1):500-2 |
1 | 87,049,374 | Catheters, Indwelling; Diabetes Mellitus, Insulin-Dependent/DT; Equipment Failure/*; Follow-Up Studies; Human; Insulin Infusion Systems/*. | Implantable continuous intravenous insulin infusion device. Restoration of flow after slow-down. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Kernstine KH; Kryjeski SR; Wigness BD; Goldenberg FJ; Rohde TD; Dorman FD; Chute EP; Rupp WM; Buchwald H. | ASAIO Trans 8703; 32(1):511-4 |
1 | 87,049,375 | Animal; Dogs; Fibrinogen/AN; Implants, Artificial/*AE; Microscopy, Electron, Scanning; Oxidation-Reduction; Platelet Aggregation; Polyethylenes/*AE; Regional Blood Flow/*; Support, U.S. Gov't, P.H.S.; Thrombosis/*ET. | Blood flow and surface-induced thrombosis. | JOURNAL ARTICLE. | The roller screw electric VAD is easier to manufacture and 25% lighter than the previously described drum cam model. This device requires 12 to 15 W to pump 6 to 8 l/min with minimal hemolysis. The motor drive has functioned for periods up to 93 days in vivo with no measurable wear. The compliance chamber volume varies by 100 cc during VAD function but does so while maintaining pressure variations below 15 mmHg. Compliance chamber volume loss of 2 to 5 cc/day is explained by gas transport through SPU. The subcutaneous sampling port provides ready access to the sealed system. | Grasel TG; Wilson RS; Lelah MD; Bielich HW; Cooper SL. | ASAIO Trans 8703; 32(1):515-20 |
1 | 87,049,376 | Aluminum/*BL/IP; Blood Proteins/AN; Deferoxamine/*TU; Hemodialysis/*MT; Human; Kinetics; Permeability; Time Factors. | Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis. | JOURNAL ARTICLE. | In order to perform quantitative in vitro and clinical studies on the removal of Al by the combined therapy of DFO administration and HD, an HPLC system for measuring DFO was established and a leaky membrane with enhanced permeability to middle molecular substances was developed. The DFO infusion caused rises in plasma Al levels (regarded as indicating the elution of accumulated Al) in patients undergoing HD. Plasma levels increased most in long-term patients and those with bone pain. Examination of Al clearances demonstrated that this increased plasma Al content passed through HD membranes at levels of more than 80 micrograms/l, and that the leaky membrane was more effective for removal of Al as well as DFO than the conventional one. Although a 1:1 complex between DFO and Al in an aqueous solution was confirmed, the formation of Al-rich complexes in vivo was suggested. It is concluded that Al-DFO complex formed in vivo can be effectively removed across the leaky membrane. | Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T. | ASAIO Trans 8703; 32(1):52-7 |
1 | 87,049,377 | Animal; Artificial Organs/*; Cardiopulmonary Bypass/*IS; Dogs; Extracorporeal Circulation/IS; Hemodynamics; Lung/*PH; Membranes, Artificial. | A portable, pumpless, AV bypass ECCO2R system, with a hollow fiber membrane lung. | JOURNAL ARTICLE. | In order to perform quantitative in vitro and clinical studies on the removal of Al by the combined therapy of DFO administration and HD, an HPLC system for measuring DFO was established and a leaky membrane with enhanced permeability to middle molecular substances was developed. The DFO infusion caused rises in plasma Al levels (regarded as indicating the elution of accumulated Al) in patients undergoing HD. Plasma levels increased most in long-term patients and those with bone pain. Examination of Al clearances demonstrated that this increased plasma Al content passed through HD membranes at levels of more than 80 micrograms/l, and that the leaky membrane was more effective for removal of Al as well as DFO than the conventional one. Although a 1:1 complex between DFO and Al in an aqueous solution was confirmed, the formation of Al-rich complexes in vivo was suggested. It is concluded that Al-DFO complex formed in vivo can be effectively removed across the leaky membrane. | Fukui Y; Kawamura T. | ASAIO Trans 8703; 32(1):521-4 |
1 | 87,049,380 | Extracorporeal Circulation/*AE; Female; Human; Infant, Newborn; Infant, Newborn, Diseases/BL/*TH; Male; Oxygen/*BL; Partial Pressure; Respiratory Distress Syndrome/BL/*TH; Thrombocytopenia/*ET. | Thrombocytopenia in neonates after extracorporeal membrane oxygenation. | JOURNAL ARTICLE. | In order to perform quantitative in vitro and clinical studies on the removal of Al by the combined therapy of DFO administration and HD, an HPLC system for measuring DFO was established and a leaky membrane with enhanced permeability to middle molecular substances was developed. The DFO infusion caused rises in plasma Al levels (regarded as indicating the elution of accumulated Al) in patients undergoing HD. Plasma levels increased most in long-term patients and those with bone pain. Examination of Al clearances demonstrated that this increased plasma Al content passed through HD membranes at levels of more than 80 micrograms/l, and that the leaky membrane was more effective for removal of Al as well as DFO than the conventional one. Although a 1:1 complex between DFO and Al in an aqueous solution was confirmed, the formation of Al-rich complexes in vivo was suggested. It is concluded that Al-DFO complex formed in vivo can be effectively removed across the leaky membrane. | Anderson HL 3d; Cilley RE; Zwischenberger JB; Bartlett RH. | ASAIO Trans 8703; 32(1):534-7 |
1 | 87,049,381 | Acute Disease; Animal; Assisted Circulation/*; Blood Pressure; Cardiac Output; Comparative Study; Dogs; Extracorporeal Circulation/*; Heart/*PP; Heart Diseases/*TH; Heart Ventricle/PP; Heart-Assist Devices/*. | Vented cardiac assistance: ECMO versus left heart bypass for acute left ventricular failure. | JOURNAL ARTICLE. | In order to perform quantitative in vitro and clinical studies on the removal of Al by the combined therapy of DFO administration and HD, an HPLC system for measuring DFO was established and a leaky membrane with enhanced permeability to middle molecular substances was developed. The DFO infusion caused rises in plasma Al levels (regarded as indicating the elution of accumulated Al) in patients undergoing HD. Plasma levels increased most in long-term patients and those with bone pain. Examination of Al clearances demonstrated that this increased plasma Al content passed through HD membranes at levels of more than 80 micrograms/l, and that the leaky membrane was more effective for removal of Al as well as DFO than the conventional one. Although a 1:1 complex between DFO and Al in an aqueous solution was confirmed, the formation of Al-rich complexes in vivo was suggested. It is concluded that Al-DFO complex formed in vivo can be effectively removed across the leaky membrane. | Eugene J; Ott RA; McColgan SJ; Roohk HV. | ASAIO Trans 8703; 32(1):538-41 |
1 | 87,049,383 | Adolescence; Adult; Aged; Female; Human; Male; Middle Age; Morbidity; Ontario; Peritoneal Dialysis, Continuous Ambulatory/*AE; Peritonitis/EP/*ET/PC; Staphylococcal Infections/EP/*ET/PC; Staphylococcus aureus; Staphylococcus epidermidis; Support, Non-U.S. Gov't. | The CAPD peritonitis rate is not improving with time. | JOURNAL ARTICLE. | In order to perform quantitative in vitro and clinical studies on the removal of Al by the combined therapy of DFO administration and HD, an HPLC system for measuring DFO was established and a leaky membrane with enhanced permeability to middle molecular substances was developed. The DFO infusion caused rises in plasma Al levels (regarded as indicating the elution of accumulated Al) in patients undergoing HD. Plasma levels increased most in long-term patients and those with bone pain. Examination of Al clearances demonstrated that this increased plasma Al content passed through HD membranes at levels of more than 80 micrograms/l, and that the leaky membrane was more effective for removal of Al as well as DFO than the conventional one. Although a 1:1 complex between DFO and Al in an aqueous solution was confirmed, the formation of Al-rich complexes in vivo was suggested. It is concluded that Al-DFO complex formed in vivo can be effectively removed across the leaky membrane. | Fenton SS; Pei Y; Delmore T; Cattran DC; Bowman C; Johnston N; Campbell I; Clarke WT; Richardson RM. | ASAIO Trans 8703; 32(1):546-9 |
End of preview. Expand
in Dataset Viewer.
Dataset Card for ohsumed
Dataset Summary
The OHSUMED test collection is a set of 348,566 references from MEDLINE, the on-line medical information database, consisting of titles and/or abstracts from 270 medical journals over a five-year period (1987-1991). The available fields are title, abstract, MeSH indexing terms, author, source, and publication type. The National Library of Medicine has agreed to make the MEDLINE references in the test database available for experimentation, restricted to the following conditions:
- The data will not be used in any non-experimental clinical, library, or other setting.
- Any human users of the data will explicitly be told that the data is incomplete and out-of-date.
Please check this readme for more details
Supported Tasks and Leaderboards
Languages
The text is primarily in English. The BCP 47 code is en
Dataset Structure
Data Instances
{'seq_id': 7770,
'medline_ui': 87120420,
'mesh_terms': 'Adult; Aged; Aneurysm/CO; Arteriovenous Fistula/*TH; Carotid Arteries; Case Report; Female; Human; Jugular Veins; Male; Methods; Middle Age; Neck/*BS; Vertebral Artery.',
'title': 'Arteriovenous fistulas of the large vessels of the neck: nonsurgical percutaneous occlusion.',
'publication_type': 'JOURNAL ARTICLE.',
'abstract': 'We describe the nonsurgical treatment of arteriovenous fistulas of the large vessels in the neck using three different means of endovascular occlusion of these large lesions, which are surgically difficult to approach and treat.',
'author': 'Vitek JJ; Keller FS.',
'source': 'South Med J 8705; 80(2):196-200'}
Data Fields
Here are the field definitions:
- seg_id: sequential identifier (important note: documents should be processed in this order)
- medline_ui: MEDLINE identifier (UI) ( used for relevance judgements)
- mesh_terms: Human-assigned MeSH terms (MH)
- title: Title (TI)
- publication_type : Publication type (PT)
- abstract: Abstract (AB)
- author: Author (AU)
- source: Source (SO)
Note: some abstracts are truncated at 250 words and some references have no abstracts at all (titles only). We do not have access to the full text of the documents.
Data Splits
The files are Train/ Test. Where the training has files from 1987 while the test files has abstracts from 1988-91
Total number of files: Train: 54710 Test: 348567
Dataset Creation
Curation Rationale
The OHSUMED document collection was obtained by William Hersh ([email protected]) and colleagues for the experiments described in the papers below. Check citation
Source Data
Initial Data Collection and Normalization
[More Information Needed]
Who are the source language producers?
The test collection was built as part of a study assessing the use of MEDLINE by physicians in a clinical setting (Hersh and Hickam, above). Novice physicians using MEDLINE generated 106 queries. Only a subset of these queries were used in the TREC-9 Filtering Track. Before they searched, they were asked to provide a statement of information about their patient as well as their information need. The data was collected by William Hersh & colleagues
Annotations
Annotation process
The existing OHSUMED topics describe actual information needs, but the relevance judgements probably do not have the same coverage provided by the TREC pooling process. The MeSH terms do not directly represent information needs, rather they are controlled indexing terms. However, the assessment should be more or less complete and there are a lot of them, so this provides an unusual opportunity to work with a very large topic sample.
The topic statements are provided in the standard TREC format
Who are the annotators?
Each query was replicated by four searchers, two physicians experienced in searching and two medical librarians. The results were assessed for relevance by a different group of physicians, using a three point scale: definitely, possibly, or not relevant. The list of documents explicitly judged to be not relevant is not provided here. Over 10% of the query-document pairs were judged in duplicate to assess inter-observer reliability. For evaluation, all documents judged here as either possibly or definitely relevant were considered relevant. TREC-9 systems were allowed to distinguish between these two categories during the learning process if desired.
Personal and Sensitive Information
No PII data is present in the train, test or query files.
Considerations for Using the Data
Social Impact of Dataset
[More Information Needed]
Discussion of Biases
[More Information Needed]
Other Known Limitations
Dataset provided for research purposes only. Please check dataset license for additional information.
Additional Information
Dataset Curators
Aakash Gupta Th!nkEvolve Consulting and Researcher at CoronaWhy
Licensing Information
CC BY-NC 4.0
Citation Information
Hersh WR, Buckley C, Leone TJ, Hickam DH, OHSUMED: An interactive retrieval evaluation and new large test collection for research, Proceedings of the 17th Annual ACM SIGIR Conference, 1994, 192-201.
Hersh WR, Hickam DH, Use of a multi-application computer workstation in a clinical setting, Bulletin of the Medical Library Association, 1994, 82: 382-389.
Contributions
Thanks to @skyprince999 for adding this dataset.
- Downloads last month
- 237